Topic Archives: Denali Therapeutics (DNLI)

Alzheimer’s Disease is on everyone’s mind these days, thanks to Biogen’s (BIIB) controversial FDA approval for marketing Aduhelm as the first Alzheimer’s treatment in years, and arguably the first disease-modifying treatment at all… so both hope (for patients and families) and greed (for investors) are back in the picture. The dispute over the approval was […]

Every year we call out a “turkey” stock teaser around Thanksgiving time and poke a bit of fun at some terrible investment ideas… … so it seems only fair to highlight a few winners as well, and this week, when we’re getting ready to close down for the holiday, seems a good time to spread […]

I got several reader questions this week about a new recommendation from Dave Lashmet at Stansberry — it looks like this was issued as a recommendation for regular Stansberry Investment Advisory subscribers, not one of Lashmet’s more expensive biotech-focused newsletters, and it’s very light on clues… but let’s see if we can give you anything […]

Here’s the lead-in to the ad that caught our readers’ attention this week: “This ‘Perfect Storm’ Stock Is Set to Deliver Big Pharma a Swift and Devastating DEATHBLOW It Won’t Come Back From… “And Launch This Little Company on A 72-Hour, $8.98 Billion All-Out SPRINT” And there’s a deadline… today, in fact, when there will […]

Ray Blanco makes (part of) his living looking for biotech moonshots, like most biotech-focused newsletter writers — and like his predecessor at Agora’s biotech and emerging tech-focused newsletter Breakthrough Technology Alert, he has often touted companies that are trying to end the scourge of Alzheimer’s Disease. Why? Well, two main reasons: First, and by far […]

Comments

  • Likely still DNLI (https://www.stockgumshoe.com/reviews/behind-the-markets/is-the-end-of-alzheimers-going-to-be-jeff-bez...

  • Michael, based upon your assessment, it appears that you feel an investment in DNLI is considerably premature. Regards, ...

  • You just have to look at The Gates foundation to see evidence of billionaires wasting billions without return and in som...

  • You are right, all the clues do point to DNLI. But all the pieces for them to have it altogether in the Alzheimer field...

  • NTRP has just completed Phase 2 trials and seem to be very successful with their drug Bryo>>>> which is adm...

  • Believe NTRP is closer to Alzheimer cure with their Phase 2 trials just ready to be announced. Have invested in a small...

  • NTRP is more likely to make an Alzheimer's-related move this year than DNLI, I expect, though don't, of course, know if ...

  • Read Ray Blanco's Alzheimer's pitch also. Wasn't going to pay thousands for any newsletter.! Researched myself and ...

  • Researched after viewing Ray Blanco...think a promising company is NTRP just finished Phase 2 with FDA trials and will a...

  • Blanco is at it again. https://pro.sevenfiguresolutions.com/p/VPI_moneybrainv4_0719/EVPIV842/?a=13&o=138585&s=162274&u...

  • What is Blanco's latest. Is it DNLI?...

  • I wonder what the correlation is between the pumps and fund rasing by the companies. Naturally these types of companie...

  • i spent two hours sleuthing -- DNLI and ESALY were the only 2 public cos i found. KH MD...

  • Wish I'd known about you before I invested in DNLI. I bought the tease, as I am totally new to investing in stocks. I ...

  • Thank you Travis. You have confirmed my own research and conclusion on Blanco's "tiny" company as DNLI and done so with ...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info